SS-31
Clinical TrialsElamipretide (MTP-131)
- Category
- Longevity & Anti-Aging
- Aliases
- Elamipretide, MTP-131, Bendavia
- Administration
- Subcutaneous injection, IV infusion (clinical)
Timing
A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.
- 1
1–2 Weeks
Effects are generally described as subtle, if present, given the compound's cellular-level mechanism.
- 2
3–4 Weeks
Some users report modestly steadier energy or reduced fatigue during exertion.
- 3
5–7 Weeks
Continued use may bring further subtle improvements in exercise tolerance for some.
- 4
8–10 Weeks
Effects, where reported, tend to build gradually rather than suddenly.
- 5
11–15 Weeks
Long-term users often describe a background sense of improved stamina rather than a distinct sensation.
- 6
16–20 Weeks
Continued observation is generally needed to notice meaningful trends.
- 7
21–24 Weeks
By this stage, users typically evaluate whether measurable markers support continued use.
⚠️ Research context only. This is not medical advice and results are not guaranteed.